Stem Cells Translational Medicine, published by Oxford University Press, is a leading open-access journal that has been at the forefront of stem cell research since its launch in 2012. With an impressive impact across various categories, it occupies Q2 in Cell Biology and is highly recognized in Q1 for both Developmental Biology and Miscellaneous Medicine in 2023. Its strong Scopus rankings highlight its significance in the fields of Biochemistry, Genetics, and Molecular Biology, achieving an outstanding percentile ranking of 93rd in Developmental Biology. The journal provides a pivotal platform for researchers, professionals, and students to publish and access cutting-edge findings that contribute to the understanding and application of stem cell technology. With a commitment to disseminating high-quality scientific knowledge, Stem Cells Translational Medicine plays a vital role in advancing research and innovation within the rapidly evolving landscape of regenerative medicine.

CELL AND TISSUE BANKING, published by Springer, is a prominent journal dedicated to advancing the fields of biomaterials, biomedical engineering, cell biology, and transplantation. With its ISSN 1389-9333 and E-ISSN 1573-6814, the journal plays a crucial role in disseminating high-quality research from its inception in 2000 to its ongoing contributions through 2024. Situated in the Netherlands, it boasts a respectable 2023 impact factor with notable quartile rankings, positioning it within the Q3 category for biomaterials, biomedical engineering, and transplantation, and Q4 for cell biology. Furthermore, its Scopus rankings underscore its relevance and influence, particularly in the fields of medicine and engineering. Although it does not currently offer open access options, the journal remains a vital resource for researchers, professionals, and students alike, fostering innovation and knowledge transfer in the critical areas of cell and tissue sustainability.

Cellular Reprogramming is a prominent academic journal published by MARY ANN LIEBERT, INC, dedicated to advancing the field of cellular biology and biotechnology. With its ISSN 2152-4971 and E-ISSN 2152-4998, this journal provides an innovative platform for researchers and professionals to share groundbreaking research findings on cellular reprogramming, stem cell biology, and regenerative medicine. Established in 2010, and actively publishing until 2024, the journal is recognized for its contributions, evidenced by its categorizations in the Q3 and Q4 quartiles across several related fields, including biotechnology and developmental biology. This peer-reviewed journal not only supports open access to scientific literature but also aims to enhance interdisciplinary collaboration among scientists. With a growing impact in the realms of biochemistry, genetics, and molecular biology, Cellular Reprogramming remains an essential resource for the dissemination of pioneering research that could shape the future of cellular therapies.

Current Stem Cell Research & Therapy, published by Bentham Science Publishers Ltd, is a leading journal dedicated to advancing the field of stem cell research. With an ISSN of 1574-888X and an E-ISSN of 2212-3946, this journal has been a valuable resource since its inception in 2006 and continues to broaden its scope through 2024. Recognized in the Q2 quartile for Medicine (miscellaneous) and ranked in the 66th percentile among its peers, the journal plays a crucial role in disseminating high-quality, peer-reviewed research that explores both the therapeutic and biological implications of stem cells. Located in the United Arab Emirates, Current Stem Cell Research & Therapy embraces a global audience of researchers, professionals, and students, providing a vibrant platform for discourse and innovation. While the journal offers subscription-based access, it remains committed to enhancing the scientific community's understanding of stem cell therapy and its applications across various medical fields.

CYTOTECHNOLOGY, an esteemed journal published by Springer, stands as a vital resource in the fields of Bioengineering, Biomedical Engineering, and Biotechnology. With an impact factor reflective of its solid position within academia, this journal encompasses a broad scope dedicated to the advancement of cytotechnological research and applications from its inception in 1987 through to its latest volumes in 2024. Based in the Netherlands, it is committed to providing researchers, professionals, and students with high-quality, peer-reviewed articles that contribute to the understanding and innovations in cytotechnology. Although currently not open access, CYTOTECHNOLOGY has garnered a commendable reputation, holding Q3 rankings in multiple categories, indicating its relevance and influence within the scientific community. Researchers are encouraged to submit their cutting-edge findings to share insights that can spark further advancements in this dynamic field.

Regenerative Therapy is a premier open-access journal dedicated to advancing the fields of biomaterials, biomedical engineering, and developmental biology. Published by Elsevier in Japan, this journal has been an influential platform since its inception in 2015, contributing significantly to the global discourse on regenerative medicine. With an impressive Q2 ranking in major categories such as Biomaterials and Biomedical Engineering, it is recognized for its quality of research and innovation. Researchers seeking to disseminate their findings or explore cutting-edge developments will find Regenerative Therapy to be invaluable, reflecting current trends and fostering collaborations across interdisciplinary boundaries. The journal offers open access, ensuring that high-quality research is available to a broad audience and enhances the impact of scholarly work in the regenerative medicine community.

Regenerative Engineering and Translational Medicine is an esteemed academic journal published by Springer Heidelberg, focusing on the interdisciplinary fields of biomaterials, biomedical engineering, and cell biology. With an ISSN of 2364-4133 and an E-ISSN of 2364-4141, the journal has carved a niche for itself since its inception in 2015, showcasing cutting-edge research that bridges the gap between scientific findings and practical applications in regenerative medicine. As a recognized platform in its field, it is currently positioned within Q3 quartiles in biomaterials, biomedical engineering, and medicine (miscellaneous), with a Scopus ranking that reflects its growing influence among peers. The journal aims to disseminate high-quality, peer-reviewed articles that highlight advancements in regenerative engineering, further advancing both theoretical and applied research. Scholars and practitioners seeking to stay at the forefront of the ever-evolving landscape of regenerative health solutions will find invaluable insights and innovations within these pages. Join a community of leading thinkers and explore the journal's comprehensive research contributions, which are crucial for fostering partnerships between academia and industry in the quest for transformative medical solutions.

CELL PROLIFERATION, published by Wiley, is a leading open-access journal that has been at the forefront of research since its inception in 1968. With an impact factor that solidifies its position in the Q1 category of both Cell Biology and Medicine (Miscellaneous), this journal serves as a premier platform for disseminating groundbreaking studies in the field of cellular and molecular biology. The journal is renowned for its rigorous peer-review process and comprehensive coverage of topics related to cell growth, division, and differentiation, making it an invaluable resource for researchers, professionals, and students alike. With its notable Scopus ranking of #30 in Biochemistry, Genetics, and Molecular Biology: Cell Biology, and a robust open access model since 2019, CELL PROLIFERATION ensures that cutting-edge research is accessible to a global audience, fostering collaboration and innovation across the scientific community. Located in the United Kingdom, the journal remains committed to enhancing the understanding of cellular processes, thereby influencing developments in medicine and biotechnology.

CELL AND TISSUE RESEARCH, published by Springer, is a premier journal dedicated to advancing the field of cell biology, histology, pathology, and forensic medicine. With a proud history dating back to its foundation in 1924 and continuing its legacy, this journal has established itself as a vital source for innovative research, facilitating the dissemination of significant findings that contribute to the understanding of cellular and tissue dynamics. Hailing from Germany, the journal exhibits an impressive standing in the academic community with a 2023 impact factor reflected in its category quartiles: Q2 in Cell Biology, Q1 in Histology, and Q1 in Pathology and Forensic Medicine. It ranks notably within multiple Scopus categories, including 32/208 in Pathology and Forensic Medicine and 13/62 in Histology, showcasing its high percentile rankings of 84th and 79th, respectively. Researchers, professionals, and students benefit from its extensive coverage and rigorous peer-review process that ensures the integrity and relevance of its published works, thus making it an essential resource in the scientific community. While it operates under a subscription model, its commitment to quality and impact makes it an indispensable journal for anyone engaged in cellular and tissue research.

Asian Journal of Pharmaceutical Sciences is a prestigious open-access journal published by Shenyang Pharmaceutical University, dedicated to advancing research and developments in the field of pharmaceutical sciences. Since its inception in 2009, the journal has successfully converged a wealth of knowledge and innovation, demonstrating an impressive track record with its open access model adopted in 2013, ensuring global dissemination of crucial research findings. With an outstanding impact factor and consistently ranked in the Q1 category for both Pharmaceutical Science and Pharmacology in 2023, it ranks among the top journals in its field, as evidenced by its impressive Scopus rankings—4th out of 183 in Pharmaceutical Science and 10th out of 313 in Pharmacology, showcasing its high relevance and credibility (98th and 96th percentiles respectively). Researchers, professionals, and students can access a diverse array of articles that encompass groundbreaking studies, reviews, and reports, solidifying the journal's position as a vital resource for anyone engaged in pharmaceutical research. With its commitment to quality and accessibility, Asian Journal of Pharmaceutical Sciences plays an essential role in fostering innovation and collaboration within the global scientific community.